Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
New Ray Medicine International Holding Ltd. ( (HK:6108) ) has issued an update.
New Ray Medicine International Holding Ltd. reported a significant revenue increase of 167.4% for the first half of 2025, reaching approximately HK$44.7 million compared to the same period in 2024. Despite the revenue growth, the company experienced a net loss increase of 82.3%, totaling approximately HK$7.5 million. The board decided against paying an interim dividend, and the company maintained a gearing ratio of zero, indicating no bank or other borrowings relative to total equity. The financial results reflect both the potential for revenue growth and the challenges in managing costs and losses, impacting stakeholders’ perspectives on the company’s financial health.
More about New Ray Medicine International Holding Ltd.
New Ray Medicine International Holding Ltd. operates in the pharmaceutical industry, focusing on the distribution and trading of pharmaceutical products. The company is incorporated in Bermuda and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 370,701
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$68.55M
For a thorough assessment of 6108 stock, go to TipRanks’ Stock Analysis page.